Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exenatide and Dapagliflozin Effects on EGP in T2DM
NCT03331289Phase 4Completed
- Sponsor
- UT Health San Antonio
- Start
- Feb 2018
- Primary completion
- Mar 2022
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of exenatide and dapagliflozin in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by UT Health San Antonio. Primary endpoint: Change in Endogenous Glucose Production From Baseline to Post-oral Glucose Load. Started Feb 2018; status: completed.
02
Drugs
exenatidedapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03331289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03331289.